Bronchiectasis Adult, COPD
Conditions
Keywords
Volara, OLE Therapy, mucous clearance
Brief summary
The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance.
Detailed description
The aim of this study is to evaluate the therapeutic effect of therapy with The Volara System on mucus clearance. Mucus volume (mL) measured by Functional Respiratory Imaging (FRI). FRI is a quantitative endpoint that identifies mucus plugs in the segmented airways. Mucus volume will be assessed based on movement of mucus plugs and/or clearance from segmental airways. CT scans are obtained to determine FRI and will be obtained and assessed at baseline and after the 4-week treatment period to assess changes in mucus volume within the airways, associated with the Volara treatment. The study will also provide insight into the mechanism of action of the therapy.
Interventions
DEVICEVolara therapy
Oscillation and Lung Expansion (OLE) therapy, is a respiratory airway clearance intervention including continuous high-frequency oscillation and continuous positive expiratory pressure
Sponsors
Baxter Healthcare Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study will be a single arm, monocentric, prospective, pilot study.
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Documented diagnosis of COPD with or without bronchiectasis. 2. Age ≥ 21 years. 3. Naive to Volara therapy. 4. FEV1 \< 80% predicted (based on pulmonary function tests within the past 12 months). 5. Daily sputum production over the prior 2 weeks. 6. Signed informed consent. 7. Stable pulmonary disease defined as no change in disease status. 8. Stable medication regimen for 30 days prior to visit 1, defined as no change in prescribed medications and adherence to their prescribed medications for pulmonary disease
Exclusion criteria
1. Anticipated requirement for hospitalisation within the next 35 days (± 1 day). 2. History of pneumothorax within the past 6 months prior to visit 1. 3. History of haemoptysis requiring embolization within the past 12 months prior to visit 1. 4. Inability or unwillingness to perform Volara System therapy as directed, without healthcare provider support. 5. Inability or unwillingness to complete study visits and/or provide follow-up data as required per the study protocol. 6. Inability to complete a 6-minute walk. 7. Actively participating in another clinical trial involving an investigational medication or device. 8. Pregnant females as verified by point of care human chorionic gonadotropin test. 9. Current Intrapulmonary Percussive Ventilation and/or oscillation and lung expansion users. 10. Participant requires a prescribed daily regimen for airway clearance with a device or with manual therapy in addition to Volara. 11. Participant requires mechanical ventilation. 12. Participants with artificial airways
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in mucus plug volume (mL) | 28 Days | Assessed based on movement of mucus plugs and/or clearance from segmental airways |
Countries
Belgium
Contacts
Primary ContactDanielle Endres, RN
Outcome results
None listed